Monomethyl auristatin E

Monomethyl auristatin E is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.

Monomethyl Auristatin E (MMAE) is a synthetic derivative of dolastatin 10, a potent antimitotic agent that inhibits cell division by blocking tubulin polymerization. Due to its high toxicity, MMAE is not used as a standalone drug but is instead conjugated to monoclonal antibodies to form antibody-drug conjugates (ADCs). These ADCs are designed to deliver the cytotoxic agent directly to cancer cells, thereby minimizing damage to healthy tissues. MMAE is utilized in the development of ADCs targeting various cancers, including lymphoma, breast cancer, and cervical cancer. Notable ADCs incorporating MMAE include brentuximab vedotin (targeting CD30) and tisotumab vedotin (targeting tissue factor).

The use of MMAE in ADCs offers several advantages:

Potent Antitumor Activity: MMAE exhibits high cytotoxicity, with an IC50 of less than 1 nM against various cancer cell lines, making it one of the most potent agents in its class.

Targeted Delivery: By conjugating MMAE to monoclonal antibodies, ADCs can specifically deliver the cytotoxic agent to tumor cells expressing the target antigen, thereby enhancing therapeutic efficacy and reducing systemic toxicity.

Overcoming Resistance: MMAE's mechanism of action allows it to be effective against tumors that have developed resistance to traditional chemotherapy agents.

Monomethyl Auristatin E is a highly potent antimitotic agent that, when conjugated to monoclonal antibodies, forms effective ADCs for targeted cancer therapy. Its ability to deliver cytotoxic agents directly to tumor cells enhances treatment efficacy while minimizing damage to healthy tissues. The development of MMAE-based ADCs represents a significant advancement in cancer treatment strategies.

Previous

Manidipine Hydrochloride丨CAS 89226-75-5

Next

Cabazitaxel丨CAS 183133-96-2